Corvus Pharmaceuticals, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Dec 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 2, 2027The maintenance fee for Humanized ANTI-CD73 Antibodies (US 11,859,007) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Aug 13, 2027The maintenance fee for Compounds and Methods for Modulating INTERLEUKIN-2-Inducible T-Cell Kinase (US 11,897,874) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,912,776 | Methods of treating cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 10,822,426 | Humanized ANTI-CD73 Antibodies In force · High confidence | In force | High confidence | |
| US 11,859,007 | Humanized ANTI-CD73 Antibodies In force · High confidence | In force | High confidence | |
| US 11,306,099 | Compounds and methods for modulating Bruton's Tyrosine Kinase In force · From the USPTO record | In force | From the USPTO record | |
| US 10,870,652 | Compounds and methods for modulating bruton's tyrosine kinase In force · From the USPTO record | In force | From the USPTO record | |
| US 11,008,314 | Compounds and Methods for Modulating INTERLEUKIN-2-Inducible T-Cell Kinase In force · High confidence | In force | High confidence | |
| US 11,897,874 | Compounds and Methods for Modulating INTERLEUKIN-2-Inducible T-Cell Kinase In force · High confidence | In force | High confidence | |
| US 12,686,677 | Compounds and Methods for Modulating INTERLEUKIN-2-Inducible T-Cell Kinase In force · Medium confidence | In force | Medium confidence | |
| US 10,793,636 | Anti-CD73 antibodies In force · From the USPTO record | In force | From the USPTO record | |
| US 10,654,825 | Processes for making triazolo[4,5D] pyramidine derivatives and intermediates thereof In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 9 no status recorded